VENCLEXTA 100 MG

In the supplied oncology record, Venetoclax is associated with CLL; SLL; AML, particularly in the settings described as CLL/SLL; AML in combination with hypomethylating agents or low-dose cytarabine in selected patients. Its pharmacological class is Selective BCL-2 inhibitor. Binds BCL-2 and releases pro-apoptotic proteins, restoring programmed cell death. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The treatment category is recorded as Targeted Therapy; BCL-2 Inhibitor. Regimen examples include Venetoclax + obinutuzumab; venetoclax + rituximab; venetoclax + azacitidine/decitabine; acalabrutinib + venetoclax. Rather than implying one universal use, these combinations show the range of contexts in which the medicine may be incorporated. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. The clinical significance of the drug is best understood through the disease-specific indication: stage, histology, treatment history, and any molecular or receptor requirement may influence eligibility. Where the same agent is listed for more than one cancer, its role should not be assumed to be interchangeable between diseases. This summary is intentionally non-prescriptive and does not include individualized dosing. Current labeling and relevant disease guidance should be reviewed when the database is used for clinical decision support.